On June 20, we were selected for the Gyeonggi-do US Bio Investment Capacity Building Program, and on June 25, the meeting and first training were held. This support project is a program that gives the first 20 companies selected in November and the final 5 companies in November the opportunity to directly contact IR with US investors.

We want to attract a different level of US investment, and through this program, we hope to have the opportunity to identify the suitability, potential, and vision of Anyfusion (Cylinder pump, ACPi system) for the US market through a company based in CA, USA, which runs the program, to establish a local subsidiary, attract investment, and explore market entry.

We have identified the characteristics of the Korean market, which is convenience-oriented and user-centered, and the characteristics of the U.S. market, which is patient-centered and safety- and effectiveness-oriented, and selected STeP as an innovative medical device that emphasizes safety and effectiveness, which is not in the Korean Innovative Medical Device System, because of the characteristics of the U.S. market, which has a patient-centered medical culture. If this is the case, we believe that the Anyfusion cylinder pump, which has been approved by the FDA as an STeP, will work in the U.S. for investment and clinical use.

Company F, which we are consulting on the support program, asked the CEO of Company F that FDA certification should be preceded by the US medical culture, which is centered on eye and breast, and FDA STeP selection technology, which is more likely to be invested by US investors. The CEO of Company F recommended applying for a breakthrough application separately from STeP. Anyfusion, including not only the cylinder pump but also the ACPi system for the US market, was highly evaluated. It is said that the selection of the project in Gyeonggi was also selected with the participation of US investment officials.

We requested the following upgrades due to the very positive situation with unrivaled clinical safety and validation in the demo at Gangbuk, Bucheon, and Incheon S hospitals. (1) Reducing the frequency of air alarms caused by low specific gravity air bubbles generated by horizontal (horizontal) pumps that are easy to stack multiple pumps because they are buoyant and cannot easily pass through the narrowed air sensor mechanism at low fluid velocity (below 50 ml/hr) in the tube, and (2) the nursing department's inability to fully master the system through multiple trainings, It is expected to be purchased after confirming through a re-demo that several pointed out points have been upgraded (scheduled to be completed in June in the laboratory), such as applying to patients immediately after one-time operation training, and solving the problem that the button shuts down when the button is selected more than necessary in an inexperienced state.

We also had a good experience in the ICU and pre-trial demo case for the first time, and we will be able to solve the problems raised in this demo and accelerate the marketization of Anyfusion in domestic and foreign markets, including major hospitals, by strengthening the design, features, and user convenience of Anyfusion with the reference of several hospitals. 

We will apply for a global demonstration support project to A University Hospital in July, and if selected, we will conduct systematic comparative research data as a post-marketing demonstration test from 4Q. It will be an important resource for the registration and registration of consumable prices for US insurers, which will be promoted simultaneously with the US FDA certification. The registration and listing of US insurance companies will be a breakthrough opportunity for the company's future and value enhancement beyond being listed on the Korean KFDA. It is important that the results of clinical safety, usability, and cost-effectiveness at the Global Empirical Support Research Center at University Hospital A are listed at a price that is reasonably improved from the Korean listed price, and the CEO of Company F, a consulting firm, knows a lot about the registration process. It is judged that it can be expedited. We are also checking the process for US insurers.

Thank you.